MARKET

ACHV

ACHV

Achieve Life Sciences Inc
NASDAQ
8.10
-0.08
-0.98%
After Hours: 8.26 +0.16 +1.98% 19:30 08/28 EDT
OPEN
8.17
PREV CLOSE
8.18
HIGH
8.22
LOW
7.95
VOLUME
988.99K
TURNOVER
--
52 WEEK HIGH
8.61
52 WEEK LOW
2.620
MARKET CAP
833.51M
P/E (TTM)
-5.2403
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ACHV last week (0817-0821)?
Weekly Report · 5d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Achieve Life Sciences (ACHV), Mereo Biopharma Group Plc (MREO) and Demant (OtherWILLF)
TipRanks · 08/17 11:40
Weekly Report: what happened at ACHV last week (0810-0814)?
Weekly Report · 08/17 09:15
Five Below, Achieve, Tronox, Brightstar, Inovio Trending
TipRanks · 08/15 09:01
Achieve Life Sciences Launches $150M ATM Equity Program
TipRanks · 08/14 21:01
Achieve Life Sciences Enters ATM Sale Agreement With Jefferies For Up To $150M In Common Stock
Benzinga · 08/14 20:31
Analysts Offer Insights on Healthcare Companies: Achieve Life Sciences (ACHV) and Idexx Laboratories (IDXX)
TipRanks · 08/13 18:00
This Vail Resorts Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday
Benzinga · 08/13 16:11
More
About ACHV
Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company. The Company focuses on addressing the global smoking health and nicotine dependence epidemic through the development and commercialization of cytisinicline. It has completed two Phase III studies with cytisinicline for smoking cessation and one Phase II study with cytisinicline in vaping cessation. Cytisinicline is a naturally occurring, plant-based alkaloid. Cytisinicline is structurally similar to nicotine and has a dual-acting mechanism of action, being both a receptor agonist and antagonist. Cytisinicline is an investigational product candidate being developed for the treatment of nicotine dependence and has not been approved by the Food and Drug Administration for any indication in the United States. Cytisinicline acts as a partial agonist/antagonist, binding to alpha-4 beta-2 nicotinic receptors in the brain and is thought to have two potential consequences in treating nicotine dependence.

Webull offers Achieve Life Sciences Inc stock information, including NASDAQ: ACHV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACHV stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACHV stock methods without spending real money on the virtual paper trading platform.